IV hydromorphone
🔵 The child is in a vaso-occlusive crisis, which is characterized by severe pain due to blocked sickled red blood cells obstructing blood flow in the microvasculature.
🔵 At 1000, the child reports pain 10/10 in the right knee, indicating severe, unrelieved pain despite ongoing care and the passage of time.
🔵 In sickle cell vaso-occlusive crises, the priority intervention is administration of opioid analgesics, usually via the IV route for rapid onset and effective pain control.
🔵 IV hydromorphone is a strong opioid analgesic commonly used for severe acute pain in hospitalized pediatric clients when non-opioid and weaker analgesics are inadequate.
🔵 The child’s vital signs are stable and oxygen saturation is 96% on room air, so there is no immediate indication for fluid resuscitation or transfusion; managing the severe pain with IV opioids is the most appropriate anticipated prescription.
pain
🔵 The nurse’s note clearly states the child’s pain increased from 7/10 to 10/10, demonstrating worsening uncontrolled pain despite already being in the unit and assessed.
🔵 The affected knee is swollen, warm, and painful, consistent with localized vaso-occlusion and inflammation, which directly causes the severe pain requiring IV opioid management.
🔵 The child’s hemoglobin is 9 g/dL and hematocrit is 18%, which are low but not unusual in chronic sickle cell disease, and this mild/moderate anemia alone does not explain the need for IV hydromorphone.
🔵 The platelet count is 450,000/mm³, slightly elevated, which can occur as a reactive process in chronic disease, but elevated platelets are not treated with opioids.
🔵 The primary indication for ordering IV hydromorphone is the child’s severe, unrelenting pain, not the lab abnormalities, so “pain” correctly completes the sentence.
Fresh frozen plasma transfusion
🔵 Fresh frozen plasma (FFP) is used to replace clotting factors in conditions like coagulopathies, liver failure, or massive bleeding, not to treat vaso-occlusive pain.
🔵 This child has no evidence of active bleeding, coagulopathy, or hemodynamic instability, so FFP is not an appropriate anticipated prescription in this situation.
Factor VIII
🔵 Factor VIII is specifically indicated for hemophilia A or certain clotting factor deficiencies, where the client has prolonged bleeding or a known factor VIII deficiency.
🔵 The child has sickle cell disease, not hemophilia, and there are no signs of bleeding or factor deficiency, so factor VIII is not appropriate here.
Hemoglobin
🔵 Although the child’s hemoglobin is low (9 g/dL), mild to moderate anemia is chronic and expected in sickle cell disease and is not the reason for prescribing IV hydromorphone.
🔵 Opioid analgesics like hydromorphone are ordered to manage severe pain, not to correct hemoglobin levels, which would instead be addressed with transfusion or disease-modifying therapy if indicated.
Platelets
🔵 The child’s platelet count is elevated (450,000/mm³), which may reflect reactive thrombocytosis, but this is not treated with IV opioids and is not an indication for hydromorphone.
🔵 Platelet abnormalities are typically managed with hematology consultation and underlying disease control, not with pain medications, so “platelets” does not logically complete the sentence.